The Medical Advisor

Butyrate, a short-chain fatty acid (SCFA) produced by gut bacteria during the fermentation of dietary fiber, plays a pivotal role in human health. While often overlooked, this compound is a crucial factor in maintaining gut integrity, supporting the immune system, regulating metabolism, and even influencing brain function. Recent research has unveiled the vast benefits of butyrate, emphasizing its role as a bridge between diet, gut microbiome, and overall well-being. The Metabolic Powerhouse: How Butyrate Fuels the Gut In the colon, butyrate serves as the primary energy source for colonocytes, the cells lining the gut, fulfilling up to 80% of their energy requirements ( Mercola, 2025 ). This energy provision is crucial for maintaining a healthy intestinal lining, preventing harmful substances from leaking into the bloodstream, and reducing systemic inflammation. Beyond energy production, butyrate enhances insulin sensitivity and regulates glucose metabolism, which is essential for main...

Semaglutide, known by the brand names Ozempic, Wegovy, Rybelsus and others, is the latest weight-loss craze to hit Hollywood and beyond. The prescription drug, which is administered via a weekly injection, is intended to treat Type 2 diabetes, but it’s widely used off-label for weight loss. They all belong to the same medication class — glucagon-like peptide-1 (GLP-1) agonists ( GLP-1 receptor agonists ).  GLP-1 agonists work by triggering insulin release, blocking sugar production in your liver, and making you feel full. But with all of these brands out there, how do you decide which is right for you? Let’s get to know some of the differences between these major GLP-1 agonist drugs. A 2021 study funded by Novo Nordisk, the drug’s maker, found using semaglutide once a week led to a 14.9% reduction in body weight among adults with obesity. There’s been such a rush on the drugs that the U.S. Food and Drug Administration lists both Ozempic and Wegovy a...

Introduction In recent years, GLP-1 receptor agonists have emerged as one of the most important breakthroughs in modern metabolic medicine. Originally developed to treat type 2 diabetes, these medications are now widely used for weight loss, cardiovascular risk reduction, and metabolic disease management . Drugs such as Ozempic, Wegovy, and Mounjaro have rapidly gained global attention for their ability to produce significant and sustained weight loss while improving multiple cardiometabolic risk factors. GLP-1 (glucagon-like peptide-1) is a natural hormone released from the gut after eating. It plays a key role in regulating blood sugar, appetite, and digestion. By mimicking or enhancing this hormone’s activity, GLP-1 drugs help reduce hunger, slow gastric emptying, improve insulin secretion, and support healthier glucose control. Over the past decade, large randomized clinical trials have demonstrated that these medications can lead to 10–20% reductions in body weight , alongside me...

⚠️ IMPORTANT MEDICAL DISCLAIMER: Retatrutide is an investigational drug and is not yet FDA-approved for weight loss or type 2 diabetes. The information below is for educational and news-tracking purposes based on clinical trial data published in 2026. Always consult a healthcare provider for currently available, approved weight-loss treatments. The landscape of medical weight loss is shifting at a breakneck pace. While semaglutide (Wegovy) and tirzepatide (Zepbound) dominated headlines over the last few years, a new powerhouse is poised to redefine obesity treatment: Retatrutide . Developed by Eli Lilly, Retatrutide is a "triple-agonist" peptide targeting three hunger-regulating receptors. With highly anticipated Phase 3 topline data officially published in early 2026, this drug is shaping up to be the most potent weight-loss medication ever developed. Here is your comprehensive, regularly updated hub on Retatrutide’s 2026 trial results, FDA time...

There is limited publicly available, peer-reviewed evidence specifically documenting success stories of Fenbendazole and Ivermectin use in treating salivary gland cancer in humans. Both drugs, traditionally used as antiparasitics (Fenbendazole in veterinary medicine and Ivermectin in humans and animals), have gained attention for their potential anticancer properties based on preclinical studies and anecdotal reports. However, clinical data remains scarce, particularly for rare cancers like salivary gland cancer. Below, we’ll summarize the available context and relevant anecdotal evidence. Background on Salivary Gland Cancer Salivary gland cancer is a rare malignancy affecting the salivary glands (e.g., parotid, submandibular, or sublingual glands), with subtypes like adenoid cystic carcinoma and mucoepidermoid carcinoma. Standard treatments include surgery, radiation, and sometimes chemotherapy, but outcomes vary depending on stage and subtype, with advanced cases often having limite...

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: June 2026 Contents: Introduction Lymphoma Case Series (25 case reports) Leukemia Case Series (14 case reports) Discussion Conclusion Important Disclaimers:  This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and drug interactions. Ivermectin and mebendazole are used off-label as complementary therapies and are not intended to replace conventional, evidence-based cancer treatments such as chemotherapy, radiotherapy, immunotherapy, targeted therapy, or hormone therapy. Any off-label use should be discussed with and supervised by a qualified physician as part of an individualized treatment plan. Non...